Theramex

Theramex is a pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis. It was established in 2018 with the acquisition of some of the assets of Teva Active Pharmaceutical Ingredients relating to Theramex Laboratories,[2] a pharmaceutical company which was based in Monaco. Brands include Ovaleap, Zoely, Seasonique, Actonel, Estreva and Lutenyl. It made an agreement with TherapeuticsMD in 2019 for exclusive licensing and supply rights to Bijuva and Imvexxy outside of the USA, Canada and Israel for which it paid a license fee of $15.5 million. In 2021, Theramex launched Livogiva,[3] Lundeos[4] (Osteoporosis) and Bijuva[5] (Menopause). That same year Theramex entered Consumer Healthcare Market with Femarelle, a non-hormonal option to treat menopause symptoms.

Theramex
IndustryPharmaceuticals
Headquarters
London, United Kingdom
Key people
Robert Stewart( CEO)[1]
Websitetheramex.com

History
  • 1954: Theramex is founded by Paul Hamel and based in Monaco.
  • 1970: The Theramex brand is established as an independent Women’s Health company, mainly serving France and Italy.
  • 1999: Merck acquires Theramex from François Rougaignon, Paul Hamel Nicolas Guérité and a financial holding company.
  • 2000: Merck KGaA acquires Theramex. The company footprint grows to serve over 25 countries.
  • 2011: Teva Pharmaceuticals acquires Theramex and introduces the Teva Women’s Health brand.
  • 2012: Theramex enters the contraception market with the introduction of a new product. Over the next few years, Theramex develops its product range and expands its portfolio, serving women’s needs in over 50 markets.
  • 2018: Teva Women’s Health is sold to CVC Capital Partners. In the latter part of 2018 there were problems with the production of its hormone replacement therapy products Evorel, FemSeven Conti and FemSeven Sequi.[6] These Hormone replacement therapy patches were not available because of issues manufacturing the glue for the patches in China.[7] The company recruited another manufacturer to assist with supply in December 2019. [8] It was not expected that normal supplies would be available before June 2020.[9]
  • 2019: Theramex expands its reach into The Netherlands, Poland, Slovakia and Romania. In June, Theramex completed separation from Teva in all EU markets.
  • 2020: Theramex opens another HQ in Warsaw, Poland. It also awards five grants to fund research into Assisted Reproductive Medicine.

References
  1. PS, Lakshmi (5 March 2020). "Theramex appoints Robert Stewart as new CEO - Latest Pharmacy News | Business | Magazine - Pharmacy Business". Retrieved 9 February 2022.
  2. yuvraj_wpt19WP. "Teva Completes Acquisition of Theramex | World Pharma Today". Retrieved 9 February 2022.
  3. "Theramex launches Livogiva®, a new teriparatide pre-filled pen for the treatment of severe osteoporosis". Theramex. 18 January 2021. Retrieved 9 February 2022.
  4. "Theramex launches Lundeos® / Fedivelle®, a new colecalciferol small soft gel capsule for the treatment of Vitamin D deficiency". Theramex. 5 May 2021. Retrieved 9 February 2022.
  5. "Theramex now has approval for Bijuva® / Bijuve® combined hormone therapy treatment for post-menopausal women*". Theramex. 29 September 2021. Retrieved 9 February 2022.
  6. "Shortage of HRTs FemSeven Conti and Sequi to continue until 2020". Chemist & Druggist. 30 April 2019. Retrieved 23 February 2020.
  7. "HRT drugs rationed amid UK shortage set to last for months". Telegraph. 24 August 2019. Retrieved 23 February 2020.
  8. "HRT products to return earlier than expected". Pharmaceutical Journal. 11 December 2019. Retrieved 23 February 2020.
  9. "The HRT crisis that forces women to buy online". Telegraph. 11 February 2020. Retrieved 23 February 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.